The effect of febuxostat in Tibetan gout patients: An observational study

Efficacy and safety of febuxostat in the treatment of Tibetan gout patients with uric acid

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900021469

Enrollment

Unknown

Registered

2019-02-22

Start date

2019-02-12

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gout and uric acid

Interventions

Observation group:?

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Tibetan patients: 18-75 years old, gender not limited; 2. It was diagnosed as gout by the doctor, and no uric acid lowering drugs were used in the first three months; 3. Stable general condition.

Exclusion criteria

Exclusion criteria: 1. Serum creatinine level 2.5 times normal upper limit, liver function (ALT, AST) >1.5 times normal upper limit; 2. Patients with skeletal muscle dysplasia combined with severe cardiovascular and cerebrovascular diseases and malignant tumors were excluded; 3. Combined use of theophylline drugs and other uric acid drugs, such as azathioprine, mercaptoprine, thiazide diuretics, aspirin (> 300 mg/d) or other salicylate drugs.

Design outcomes

Primary

Measure	Time frame
Blood uric acid;Uratoma;	—

Countries

China

Contacts

Public ContactRui Guo

Hospital of the People's Government of Tibet Autonomous Region in Chengdu Office

264127281@qq.com+86 13540265453

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026